Tagged with P

Roundup The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy can kickstart the domestic Filipino pharma industry.   Alvotech and DKSH have expanded their partnership to commercialize six new biosimilar…

Europe Ole Olesen, executive director of the European Vaccine Initiative (EVI), shares the highlights of his first nine months in the job grappling with a global pandemic; the mission of EVI to support the development of non-commercially viable vaccines as well as to create a European vaccine infrastructure; as well as…

USA Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive order on medicine pricing, its wider impact on other high income economies, and why a Democratic victory in the upcoming presidential election will not see this issue go away.  …

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park, gives an insider’s take on the opportunities and challenges for pharma companies in the large, innovation-friendly, but often misunderstood, Japanese market.   Japan is the world’s third-largest economy and second-largest pharmaceutical and medtech market, and yet it still holds a…

Opinion Robert Hall of Ardent Search, an executive search boutique specialised in the life sciences and healthcare sectors, highlights the five key points for recruiters and pharma companies to consider when hiring market access professionals to work in Asia.   Whether it is an established or a developing market, access is…

Roundup Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine.   AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership…

Gilead With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and CEO Daniel O’Day and Gilead vice-president and general manager of the Asia 5 region (Singapore, South Korea, Hong Kong, Taiwan, Malaysia) Andrew Hexter are determined to stress…

Norway Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer…

Switzerland In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a free trade agreement between the two countries, and why Switzerland needs to “wake up” to remain globally competitive.   In…

Norway Norway, more well-known internationally as an innovation hub for oil & gas and marine biology, is attempting to reverse the trend of reducing numbers of clinical trials and cultivate a domestic healthcare research industry. Drawing on the country’s comprehensive health registries, universal healthcare system, links with its Nordic neighbours, and…

India The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next three years, with exports predicted to grow by eight to 14 percent, according to a recent KPMG report.   The…

Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’.   Data is the new oil, but biomedical data – despite its abundance…